# A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）

> **NCT02137681** · PHASE3 · WITHDRAWN · sponsor: **Shandong University**

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02137681
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-05
- **Primary completion:** 2015-01
- **Final completion:** 2016-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No eligible patient was enrolled.
- **Last updated:** 2016-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137681, "A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02137681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*